Endo International’s (ENDP) “Buy” Rating Reiterated at Mizuho
Mizuho reiterated their buy rating on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a report published on Wednesday morning, MarketBeat reports. They currently have a $12.00 target price on the stock, down from their prior target price of $14.00.
“We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued.”,” the firm’s analyst commented.
A number of other equities analysts have also commented on ENDP. ValuEngine lowered shares of Endo International from a buy rating to a hold rating in a research report on Sunday, December 31st. Cantor Fitzgerald reduced their price target on shares of Endo International from $9.00 to $7.00 and set a neutral rating on the stock in a research report on Friday, November 10th. Zacks Investment Research upgraded shares of Endo International from a strong sell rating to a hold rating in a research report on Monday, September 25th. Piper Jaffray Companies restated a hold rating and issued a $9.00 price target on shares of Endo International in a research report on Sunday, September 17th. Finally, Vetr upgraded shares of Endo International from a buy rating to a strong-buy rating and set a $8.92 price target on the stock in a research report on Tuesday, December 26th. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $11.27.
Endo International (NASDAQ ENDP) opened at $8.69 on Wednesday. The company has a market cap of $1,949.53, a PE ratio of -0.39, a price-to-earnings-growth ratio of 3.00 and a beta of 0.59. Endo International has a 12-month low of $5.77 and a 12-month high of $17.63. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. The firm had revenue of $786.90 million for the quarter, compared to analyst estimates of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.01 earnings per share. equities research analysts predict that Endo International will post 3.67 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Endo International by 64.0% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 135,627 shares of the company’s stock worth $1,160,000 after buying an additional 52,927 shares during the last quarter. LMR Partners LLP bought a new stake in shares of Endo International during the third quarter worth approximately $148,000. Van ECK Associates Corp raised its stake in shares of Endo International by 67.1% during the third quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after buying an additional 136,873 shares during the last quarter. Alps Advisors Inc. raised its stake in shares of Endo International by 9.3% during the third quarter. Alps Advisors Inc. now owns 250,511 shares of the company’s stock worth $2,146,000 after buying an additional 21,373 shares during the last quarter. Finally, Gamco Investors INC. ET AL raised its stake in shares of Endo International by 76.2% during the third quarter. Gamco Investors INC. ET AL now owns 110,500 shares of the company’s stock worth $946,000 after buying an additional 47,800 shares during the last quarter. 93.06% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Endo International’s (ENDP) “Buy” Rating Reiterated at Mizuho” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/endo-internationals-endp-buy-rating-reiterated-at-mizuho/1797466.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with Analyst Ratings Network's FREE daily email newsletter.